Current and future considerations for oncology biosimilars in 2020
from Pharmacy Times
The U.S. healthcare system expects 2020 to be a year of major cost savings, in part because of the projected significant traction from 3 major biosimilars for rituximab (Rituxan), bevacizumab (Avastin), and trastuzumab (Herceptin), which accounted for a total of $19.4 billion in sales in 2018. Genentech’s October 2014 shift of its distribution model for rituximab, bevacizumab, and trastuzumab from an open-channel to a limited-distribution model has since cost US hospitals approximately $300 million, according to estimates. The health care system has the potential to realize cost savings of up to $5 billion in 2020 with oncology biosimilars.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063